chetomin has been researched along with Glioma in 2 studies
chetomin: C31H30N6O6S4, similar to epipolythiodioxopiperazines
chetomin : An organic heteropentacyclic compound of the class of epipolythiodioxopiperazine. Isolated from Chaetomium globosum and Farrowia seminuda, it exhibits immunosuppressive activity.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although siRNA and chetomin show distinct modes of action, both attenuated the hypoxia-induced radioresistance of malignant glioma cell lines U251MG (DMF10: 1." | 7.76 | HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. ( Bache, M; Hahnel, A; Kappler, M; Kessler, J; Rot, S; Vordermark, D; Wichmann, H, 2010) |
| "Although siRNA and chetomin show distinct modes of action, both attenuated the hypoxia-induced radioresistance of malignant glioma cell lines U251MG (DMF10: 1." | 3.76 | HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. ( Bache, M; Hahnel, A; Kappler, M; Kessler, J; Rot, S; Vordermark, D; Wichmann, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, H | 1 |
| Li, Y | 1 |
| Shu, M | 1 |
| Tang, J | 1 |
| Huang, Y | 1 |
| Zhou, Y | 1 |
| Liang, Y | 1 |
| Yan, G | 1 |
| Kessler, J | 1 |
| Hahnel, A | 1 |
| Wichmann, H | 1 |
| Rot, S | 1 |
| Kappler, M | 1 |
| Bache, M | 1 |
| Vordermark, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for chetomin and Glioma
| Article | Year |
|---|---|
Hypoxia-inducible factor-1alpha blocks differentiation of malignant gliomas.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Cobalt; Colforsin; | 2009 |
HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carbonic Anhydrase IX; Carbonic Anhydrases; Ce | 2010 |